This genomic landscape study of 906 patients with IDH-wildtype GBMs treated at a tertiary cancer referral center demonstrated that 4.1% harbored potentially druggable activating F3T3 fusions with recurrent structural isoforms; characteristic associated mutational, copy-number, and methylation profiles; and clinical outcomes slightly better than patients with F3T3-wildtype tumors despite occurring in older individuals. This evidence concerns the gene IDH2 and cancer.